Comparative Pharmacology
Head-to-head clinical analysis: DETROL versus PROPANTHELINE BROMIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DETROL versus PROPANTHELINE BROMIDE.
DETROL vs PROPANTHELINE BROMIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive muscarinic receptor antagonist, primarily targeting M3 receptors in the bladder, reducing detrusor muscle contractions and increasing bladder capacity.
Antimuscarinic; competitively blocks acetylcholine at postganglionic muscarinic receptors, inhibiting parasympathetic nerve impulses.
2 mg orally twice daily; may increase to 4 mg daily in divided doses based on response.
15 mg orally 3 times daily before meals and 30 mg at bedtime; initial dose may be 15 mg 3 times daily.
None Documented
None Documented
Terminal half-life 6.9 hours (range 4-10 hours) for tolterodine; 7.7 hours (range 5-13 hours) for active 5-hydroxymethyl metabolite; prolonged in hepatic impairment (up to 3-fold).
Terminal half-life 2.5-4 hours; clinically, dosing every 6 hours maintains therapeutic levels.
Renal: 77% (as metabolites, <1% unchanged); Fecal: 17%; Biliary: minor.
Approximately 70% renal (tubular secretion) as metabolites and unchanged drug; 30% biliary/fecal.
Category C
Category A/B
Anticholinergic
Anticholinergic